BOCA RATON, FL / ACCESS Newswire / December 8, 2025 / In recent years, LIXTE (NASDAQ:LIXT) has been defined by LB-100, its first-in-class PP2A inhibitor with a mechanism that unlocks new therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback